Difference between revisions of "IE Dublin Miinalainen I"
From Bioblast
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{O2k-Network Lab | ||
| | |institution=NICB | ||
NICB | |||
Centre for Bioanalytical Sciences (CBAS) | Centre for Bioanalytical Sciences (CBAS) | ||
Dublin City University | Dublin City University | ||
|address=Glasnevin | |||
Glasnevin | |||
|city=Dublin | |city=Dublin | ||
|country=Ireland | |country=Ireland | ||
|MiPNetLab=Miinalainen | |MiPNetLab=Miinalainen Ilkka | ||
|info=IOC47 | |Status=O2k 2008-2013 | ||
|info=[[MiPNet13.04 IOC47|IOC47]] | |||
|Info=[http://www.oroboros.at/index.php?id=1244 IE_Dublin_MiinalainenI] | |Info=[http://www.oroboros.at/index.php?id=1244 IE_Dublin_MiinalainenI] | ||
}} | }} | ||
== Feedback == | |||
* ''First of all I´d like to say that I´m very happy with the O2k system. I have used it quite a lot lately, mainly doing phosphorylation control titrations with intact podocytes and I have not have any problems, except for a few small ones relating to software.'' - '''[[Miinalainen IJ|Ilkka J Miinalainen]]''' (2009) | |||
Latest revision as of 09:49, 10 June 2016
IE Dublin Miinalainen I
| O2k-Network Lab | NICB
Centre for Bioanalytical Sciences (CBAS) Dublin City University |
|---|---|
| Address | Glasnevin, |
| City | Dublin |
| State/Prov | |
| Country | Ireland |
| Weblink | |
| Contact | |
| Team | Miinalainen Ilkka |
| Team previous | |
| Status | O2k 2008-2013 |
| Oroboros Events | IOC47 |
| Topics |
O2k-Publications
| Published | Reference | |
|---|---|---|
| Raesaenen 2016 Proc Natl Acad Sci U S A | 2016 | Räsänen M, Degerman J, Nissinen TA, Miinalainen I, Kerkelä R, Siltanen A, Backman JT, Mervaala E, Hulmi JJ, Kivelä R, Alitalo K (2016) VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 113:13144-49. |
O2k-Abstracts
update please
Feedback
- First of all I´d like to say that I´m very happy with the O2k system. I have used it quite a lot lately, mainly doing phosphorylation control titrations with intact podocytes and I have not have any problems, except for a few small ones relating to software. - Ilkka J Miinalainen (2009)
